Yazarlar : Russell S, Federspiel M, Peng K et al

Yayın : Mayo Clin Proc

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/remission-disseminated-cancer-after-systemic-oncolytic-virotherapy?tsid=5

Konu : Myelom

Literatür İçeriği :  MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

Literatür Arşivi